Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Magnaspartate 243mg Powder for Oral Solution
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Magnesium aspartate dihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for
Magnaspartate is a mineral preparation and contains the active ingredient magnesium aspartate dihydrate equivalent to 243 mg (10 mmol) of magnesium. Magnaspartate is used in the treatment and prevention of magnesium deficiency in adults and children aged 2 years and above. You must talk to a doctor if you do not feel better or if you feel worse after taking this medicine. 2.
What you need to know before you take it
e MAGNASPARTATE
Do not take MAGNASPARTATE:
- if you are allergic to magnesium aspartate dihydrate or any of the other ingredients of this medicine (listed in section 6).
- if you have severe kidney problems
- if you have a very slow heart rhythm (called 'bradycardia') Warnings and precautions Talk to your doctor or pharmacist before taking Magnaspartate: If you have switched from another magnesium medicine to ensure that treatment with Magnaspartate does not make you feel unwell and that you can continue to receive the correct dose of magnesium. Other medicines and MAGNASPARTATE Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Magnaspartate can affect the way some other medicines work. Also, some other medicines can affect the way Magnaspartate works. In particular, you must allow a time interval of 2-3 hours between the taking MAGNASPARTATE and the following medicines. 1
- Cellulose sodium phosphate, used to prevent kidney stones
- EDTA, used in hospital for high calcium levels
- Flourides, used for preventing tooth decay
- Tetracyclines, Nitrofurantoin, Nitroxoline, antibiotic to treat infections
- Aminoquinolines, medicines to treat malaria
- Quinidine and quinidine derivatives, medicines to treat heart rhythm disorders
- Penicillamine, medicine used to treat severe rheumatoid arthritis and used in Wilson's disease
- Iron, to treat anemia
- Bisphosphonates, to treat osteoporosis
- Eltrombopag, to correct bleeding deficiency The following medicines may cause magnesium deficiency. Your doctor may decide to adjust your daily dose of magnesium.
- Aminoglycosides, antibiotics used to treat infections e.g. gentamicin, streptomycin and neomycin
- Certain medicines used to treat cancer such as cisplatin and EGF-receptor antagonists such as cetuximab and erlotinib
- Ciclosporins, medicines used to suppress the body's immune system e.g. following an organ transplant
- Water tablets (Diuretics), medicines used to treat blood pressure or heart failure e.g. thiazide, furosemide, bumetanide
- Proton Pump Inhibitors, medicines used to treat high acid in the stomach or oesophagus. e.g. omeprazole, pantoprazole
- Amphotericin B, antibiotic that fights fungal infections in the body
- Rapamycin, medicine used to suppress the body's immune system e.g. following an organ transplant
- Pentamidine, medicine to treat infections such as pneumonia
- Foscarnet, an antiviral medication MAGNASPARTATE with drinks Magnaspartate can be taken with water, tea or orange juice. Pregnancy, breast-feeding and fertility Magnaspartate can be used during pregnancy and during breast-feeding without concerns. Based on long-term experience, no effects of magnesium on male and female fertility are anticipated. Driving and using machines Magnaspartate has no or negligible influence on the ability to drive and use machines. MAGNASPARTATE contains sucrose and sodium. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. Contains 2.706 g of sucrose per sachet. This should be taken into account in patients with diabetes mellitus. In case of frequent/and or permanent use, may be harmful to the teeth. This medicine contains less than 1 mmol sodium (23 mg) per sachet, that is to say essentially 'sodium-free'.
2
3.
How to take it
MAGNASPARTATE
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is Adults (over 18 years) 1-2 sachets daily (equal to 243-486 mg magnesium). Use in children and adolescents Children and Adolescents (10 to 18 years) One sachet daily (equal to 243 mg magnesium) dissolved in 50-200ml of water, tea, or orange juice. Children (4 to 10 years) One sachet daily (equal to 243 mg magnesium) dissolved in 50-200ml of water, tea, or orange juice. Alternatively, for a half dosage, use half the volume of 1 sachet dissolved in 50-200ml of water (equal to 121.5 mg magnesium). Children (2 to 4 years) Half the volume of 1 sachet dissolved in 50-200ml water (equal to 121.5 mg magnesium). Renal patients: No dose adjustment is required in mild to moderate renal failure. The blood magnesium levels of children and adolescents (12 to 18 years) and renal patients need to be monitored at regular intervals. The duration of magnesium supplementation will depend upon the clinical needs of each patient. Directions for use: Dissolve one sachet of Magnaspartate in 50-200ml water, tea, or orange juice. Stir until the solution in water is cloudy to transparent. In orange juice or tea inactive particles will be visible. Drink immediately or within 24 hours if made with bottled water and stored below 25°C. If you are unable to swallow and have a gastric, duodenal or nasal feeding tube, Magnaspartate in 200 ml water can be administered through the tube immediately after preparation or within 24 hours if made with bottled water and stored below 25°C. If you take more MAGNASPARTATE than you should No side effects are expected, if your kidneys work properly. Any excessive amount of magnesium will be excreted through your kidneys. If you have taken more of this medicine than directed, or if a person with severe kidney problems or if a child accidentally has taken this medicine, please contact your doctor or local hospital casualty department for judgement of the risk and advice. If you forget to take MAGNASPARTATE Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Uncommon (may affect 1 to 10 users in 1,000): Soft stools to diarrhoea at the beginning of treatment (harmless and will usually decrease in frequency as the treatment advances). Very rare (may affect less than 1 user in 10,000): Fatigue if Magnaspartate is used for a longer period of time. 3
If you get any side effects such as diarrhoea, you should temporarily interrupt the treatment. After the symptoms improve you can restart treatment, with a reduced dosage. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via (see details below). United Kingdom (Northern Ireland)
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
By reporting side effects, you can help provide more information on the safety of this medicine.
5.
How to store it
MAGNASPARTATE
Do not store above 25°C. When Magnaspartate has been dissolved in water, orange juice or tea, the solution should be consumed immediately or within 24 hours when dissolved in bottled water and stored below 25°C. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the sachet and carton after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
Contents of the pack and other information
What MAGNASPARTATE contains
- The active substance is magnesium. One sachet (6.5 g) contains magnesium aspartate dihydrate 3246 mg; magnesium content: 243 mg.
- The other ingredients are sucrose, citric acid monohydrate, peach/apricot flavour, saccharin sodium, silica, colloidal anhydrous What MAGNASPARTATE looks like and contents of the pack White powder with a peach/apricot-like flavour. Magnaspartate is available in packs of 10 sachets or 20 sachets. Not all pack sizes may be marketed. Marketing Authorisation Holder Kora Corporation Ltd t/a Kora Healthcare 20 Harcourt Street, Dublin 2, D02 H364, Ireland Manufacturer Recipharm Höganäs AB, Sporthallsvägen 6, Höganäs, 26335, Sweden Lusomedicamenta Sociedade Tecnica Farmaceutica, S.A. Estrada Consiglieri Pedroso, 69 – B, Queluz, Barcarena, 2730-055, Portugal 4
This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names: United Kingdom (NI&GB) Belgium, Netherlands, Ireland
Magnaspartate 243 mg powder for oral solution Magnence 243 mg powder for oral solution
This leaflet was last revised April 2024
5
Frequently asked questions about Magnaspartate 243mg Powder for Oral Solution
How do I take Magnaspartate 243mg Powder for Oral Solution?
Magnaspartate 243mg Powder for Oral Solution comes as oral solution containing 243mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Magnaspartate 243mg Powder for Oral Solution?
The active substance in Magnaspartate 243mg Powder for Oral Solution is magnesium aspartate dihydrate.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Magnaspartate 243mg Powder for Oral Solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Magnaspartate 243mg Powder for Oral Solution without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: magnesium aspartate dihydrate
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Magnaspartate is indicated for the treatment and prevention of magnesium deficiency in adults and children aged 2 years and above.
4.2. Posology and method of administration
The duration of magnesium treatment required will depend on the clinical circumstances of each patient.
It is recommended that serum magnesium levels should be monitored at regular intervals e.g. every 3-6 months, particularly in children and in patients with renal impairment.
Posology
Adults (> 18 years)
1-2 sachets daily (243-486 mg magnesium or 10-20 mmol magnesium)
Children and adolescents: 10 to 18 years
One sachet daily (equal to 243 mg magnesium) dissolved in 50-200ml of water, tea, or orange juice.
Children: 4-10 years
One sachet daily (equal to 243 mg magnesium) dissolved in 50-200ml of water, tea, or orange juice. Alternatively, for a half dosage, use half the volume of 1 sachet dissolved in 50-200ml of water (equal to 121.5 mg magnesium).
Children: 2 to 4 years
Half the volume of 1 sachet dissolved in 50-200ml water (equal to 121.5 mg magnesium).
The safety and efficacy of Magnaspartate in children below 2 years has not been established.
Renal patients:
Magnaspartate 243 mg is contraindicated in patients with severe renal impairment (see section 4.3).
There is no dose adjustment necessary in patients with mild to moderate renal impairment.
Elderly:
No dose adjustment is necessary.
Method of administration
For oral use after solution in water, tea or orange juice.
Magnaspartate can be dissolved in 50-200mL water, tea or orange juice.
Stir until the solution in water is cloudy to transparent. In orange juice or tea inactive particles will be visible. The solution should be taken immediately following reconstitution or within 24 hours when dissolved in bottled water and stored below 25°C.
Note
If necessary, Magnaspartate in 200ml water can be administered via a gastric, duodenal, and nasal feeding tube. This should be administered immediately following reconstitution or within 24 hours when dissolved in bottled water and stored below 25°C.
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Severe renal impairment (glomerular filtration rate < 30 ml/min)
• Disorders of Cardiac conduction (bradycardia)
4.4. Special warnings and precautions for use
In the case of confirmed magnesium deficiency, concomitant hypocalcaemia and hypokalaemia should be suspected and corrected if confirmed since magnesium deficiency is frequently secondary to those conditions.
If an undesirable effect occurs, such as diarrhoea, the therapy should be temporarily interrupted and can be restarted after improvement and /or elimination of the symptoms with a reduced dosage.
The bioavailability of magnesium preparations can vary; therefore, caution should be exercised when switching between magnesium preparations to ensure tolerability and equivalent therapeutic effect.
Excipients:
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
Contains 2.706 g of sucrose per sachet. This should be taken into account in patients with diabetes mellitus. May be harmful to the teeth.
This medicinal product contains less than 1 mmol sodium (23 mg) per sachet, that is to say essentially 'sodium-free'
4.5. Interaction with other medicinal products and other forms of interaction
As magnesium and other medicinal products may mutually influence each other's absorption, a time interval of 2 to 3 hours should generally be respected if possible.
This specifically applies to:
• Cellulose sodium phosphate; edetate disodium: concurrent use with magnesium supplements may result in binding of magnesium; patients should be advised not to take magnesium supplements within 1 hour of cellulose sodium phosphate or edentate disodium.
• Fluorides and tetracycline: if they must be used, the doses must be separated by 2 to 3 hours or more to prevent their admixture in the gut.
• Aminoquinolines, quinidine and quinidine derivatives nitrofurantoin, penicillamine, iron, bisphosphonates, eltrombopag, nitroxoline: to avoid impairment of absorption, magnesium preparations should be taken 3 to 4 hours before or after the administration of those drugs.
Because of increased magnesium losses, a dose adjustment of magnesium may be necessary when taking the following substances:
• Aminoglycoside antibiotics, cisplatinum and ciclosporin A
• Diuretics (such as thiazide and furosemide),
• EGF-receptor antagonists (such as cetuximab and erlotinib),
• proton pump inhibitors (such as omeprazole and pantoprazole) and
• viral DNA polymerases-inhibiting foscarnet, pentamidine, rapamycin and amphotericin B
For further information on mechaninsms of drug interactions see section 5.2.
4.6. Fertility, pregnancy and lactation
Pregnancy
A large amount of data on pregnant women over 16 weeks gestation (more than 1000 pregnancy outcomes) indicate no malformative nor feto/neonatal toxicity of magnesium.
Magnaspartate can be used during pregnancy if clinically needed.
Administration of aminoglycoside antibiotics should be avoided during this period, as there are indications of interactions (see 4.5).
Lactation
Magnaspartate can be used during breast-feeding.
Magnesium aspartate/metabolites are excreted in human milk, but at therapeutic doses of Magnaspartate no effects on the breastfed newborns/infants are anticipated.
Fertility
Based on long-term experience, no effects of magnesium on male and female fertility are anticipated.
4.7. Effects on ability to drive and use machines
Magnaspartate has no or negligible influence on the ability to drive and use machines.
4.8. Undesirable effects
The evaluation of undesirable effects is based on the following frequencies:
Very common (≥1/10);
common (≥1/100 to <1/10);
uncommon (≥1/1,000 to <1/100);
rare (≥1/10,000 to <1/1,000);
very rare (<1/10,000);
not known (cannot be estimated from the available data).
Listed by MedDRA System Organ Class:
Gastrointestinal disorders
Frequency: Uncommon
Undesirable Effects: Soft stools or diarrhoea following high dosage
General disorders and administration site conditions
Frequency: Very rare
Undesirable Effects: Fatigue if used long-term
At high dosage diarrhoea or gastrointestinal irritation may occur. If diarrhoea occurs, the daily dose should be reduced and gradually increased later if needed.
In cases of high doses and long-term use fatigue may be experienced. This may be an indication that an elevated magnesium level has been achieved. Hypermagnesemia is rare after oral administration of magnesium salts, unless there is renal dysfunction.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
4.9. Overdose
In the case of intact renal function, magnesium toxication due to oral overdose of magnesium is not expected. Only in the case of severe renal insufficiency a cumulation of magnesium may arise in combination with a manifested intoxication.
In general, plasma concentrations up to 2 mmol/l are well tolerated.
Intoxication symptoms:
Blood pressure fall, nausea, vomiting, hyporeflexia, somnolence, changes in the electrocardiogram, respiratory depression and cardiac arrest.
Intoxication therapy:
Intravenous administration of calcium and slow intravenous administration of 0.5 – 2 mg neostigmine methylsulfate;
Intravenous and per-oral administration of isotonic sodium chloride solution; ventilatory and
circulatory support;
In case of renal insufficiency: haemodialysis.
🇷🇴 Known in Romania as
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Magnesium aspartate dihydrate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
- MAGNESII SULFURICI POLPHARMA 200 mg/ml prescription partial — not the same combinationMAGNESII SULFAS · injection / infusion
- MAGNESIUM SULFATE KALCEKS 200 mg/ml prescription partial — not the same combinationMAGNESII SULFAS · injection / infusion
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
🇵🇱 Known in Poland as
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Magnesium aspartate dihydrate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
- Slow-Mag partial — not the same combinationMagnesii chloridum · taken by mouth
- Magnezu siarczan partial — not the same combinationMagnesii sulfas · taken by mouth
- Magnezu siarczan GEMI partial — not the same combinationMagnesii sulfas · taken by mouth
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
💬 Ask about this leaflet
Ask anything about Magnaspartate 243mg Powder for Oral Solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.